NxStage Medical Inc. (NASDAQ:NXTM) shares traded up 1.2% during trading on Tuesday . The stock traded as high as $22.16 and last traded at $21.92, with a volume of 159,158 shares traded. The stock had previously closed at $21.66.

Several research analysts have commented on the company. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Wednesday, July 6th. Northland Securities raised NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 price target on the stock in a research report on Tuesday, June 28th. BTIG Research reaffirmed a “buy” rating and set a $27.00 price target on shares of NxStage Medical in a research report on Tuesday, June 7th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $21.00 price target on shares of NxStage Medical in a research report on Friday, June 3rd. Finally, Wells Fargo & Co. reaffirmed a “sell” rating on shares of NxStage Medical in a research report on Thursday, May 5th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. NxStage Medical currently has a consensus rating of “Buy” and an average price target of $24.50.

The firm’s 50-day moving average is $20.89 and its 200 day moving average is $17.76. The company’s market cap is $1.43 billion.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The business earned $89.20 million during the quarter, compared to analysts’ expectations of $88.40 million. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.09) EPS. Analysts predict that NxStage Medical Inc. will post ($0.12) earnings per share for the current fiscal year.

In related news, President Joseph E. Turk, Jr. sold 1,500 shares of the stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $17.89, for a total value of $26,835.00. Following the completion of the transaction, the president now owns 103,280 shares of the company’s stock, valued at $1,847,679.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A number of hedge funds and institutional investors have modified their holdings of the stock. Jennison Associates LLC increased its position in shares of NxStage Medical by 32.9% in the fourth quarter. Jennison Associates LLC now owns 1,395,174 shares of the medical device company’s stock worth $30,568,000 after buying an additional 345,394 shares in the last quarter. Jennison Associates increased its position in shares of NxStage Medical by 12.0% in the third quarter. Jennison Associates now owns 1,049,780 shares of the medical device company’s stock worth $16,555,000 after buying an additional 112,792 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of NxStage Medical by 6.5% in the fourth quarter. Wells Fargo & Company MN now owns 1,450,307 shares of the medical device company’s stock worth $31,777,000 after buying an additional 88,286 shares in the last quarter. Trexquant Investment LP increased its position in shares of NxStage Medical by 142.4% in the fourth quarter. Trexquant Investment LP now owns 57,700 shares of the medical device company’s stock worth $1,264,000 after buying an additional 33,900 shares in the last quarter. Finally, OppenheimerFunds Inc. increased its position in shares of NxStage Medical by 2.0% in the fourth quarter. OppenheimerFunds Inc. now owns 728,153 shares of the medical device company’s stock worth $15,954,000 after buying an additional 14,578 shares in the last quarter.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.